Patents by Inventor J. Glenn Morris
J. Glenn Morris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130338018Abstract: The subject invention pertains to an assay and a method for diagnosing, identifying and/or differentiating microorganisms, and in particular bacteria such as Mycobacterium spp. within biological samples. The present invention also relates to assays, gene arrays, probes and primers, nucleic acids and methods for detecting microorganisms in a sample.Type: ApplicationFiled: January 13, 2011Publication date: December 19, 2013Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.Inventors: Jianli Dai, J. Glenn Morris
-
Publication number: 20130164374Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: ApplicationFiled: February 21, 2013Publication date: June 27, 2013Applicant: Intralytix, Inc.Inventors: J. Glenn MORRIS, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20120148505Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: ApplicationFiled: August 22, 2011Publication date: June 14, 2012Applicant: Intralytix, Inc.Inventors: J. Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Patent number: 8003323Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: GrantFiled: November 4, 2008Date of Patent: August 23, 2011Assignee: Intralytix, Inc.Inventors: J. Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20090053144Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: ApplicationFiled: November 4, 2008Publication date: February 26, 2009Applicant: Intralytix, IncInventors: J. Glenn MORRIS, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Patent number: 7459272Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: GrantFiled: December 2, 2003Date of Patent: December 2, 2008Assignee: Intralytix, Inc.Inventors: J. Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20040247569Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: ApplicationFiled: December 2, 2003Publication date: December 9, 2004Applicant: Intralytix, Inc.Inventors: J. Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20040208853Abstract: Methods and devices for sanitation using bacteriophage are disclosed. According to one embodiment of the present invention, a method for sanitation using at least one bacteriophage includes the steps of (1) storing the at least one bacteriophage in a container; and (2) applying the at least one bacteriophage to a surface to be sanitized with a dispersing mechanism. According to another embodiment of the present invention, a sanitation device that dispenses at least one bacteriophage includes a container, at least one bacteriophage stored in the container, and a dispersing mechanism that disperses the at least one bacteriophage from the container.Type: ApplicationFiled: December 11, 2003Publication date: October 21, 2004Applicant: Intralytix, Inc.Inventors: Alexander Sulakvelidze, J. Glenn Morris, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20040191224Abstract: Methods and devices for sanitation using bacteriophage are disclosed. According to one embodiment of the present invention, a method for sanitation using at least one bacteriophage includes the steps of (1) storing the at least one bacteriophage in a container; and (2) applying the at least one bacteriophage to a surface to be sanitized with a dispersing mechanism. According to another embodiment of the present invention, a sanitation device that dispenses at least one bacteriophage includes a container, at least one bacteriophage stored in the container, and a dispersing mechanism that disperses the at least one bacteriophage from the container.Type: ApplicationFiled: December 11, 2003Publication date: September 30, 2004Applicant: Intralytix, Inc.Inventors: Alexander Sulakvelidze, J. Glenn Morris, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Patent number: 6699701Abstract: Methods and devices for sanitation using bacteriophage are disclosed. According to one embodiment of the present invention, a method for sanitation using at least one bacteriophage includes the steps of (1) storing the at least one bacteriophage in a container; and (2) applying the at least one bacteriophage to a surface to be sanitized with a dispersing mechanism. According to another embodiment of the present invention, a sanitation device that dispenses at least one bacteriophage includes a container, at least one bacteriophage stored in the container, and a dispersing mechanism that disperses the at least one bacteriophage from the container.Type: GrantFiled: January 11, 2001Date of Patent: March 2, 2004Assignee: Intralytix, Inc.Inventors: Alexander Sulakvelidze, J. Glenn Morris, Jr., Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20040029250Abstract: Methods and devices for sanitation using bacteriophage are disclosed. According to one embodiment of the present invention, a method for sanitation using at least one bacteriophage includes the steps of (1) storing the at least one bacteriophage in a container; and (2) applying the at least one bacteriophage to a surface to be sanitized with a dispersing mechanism. According to another embodiment of the present invention, a sanitation device that dispenses at least one bacteriophage includes a container, at least one bacteriophage stored in the container, and a dispersing mechanism that disperses the at least one bacteriophage from the container.Type: ApplicationFiled: January 11, 2001Publication date: February 12, 2004Inventors: Alexander Sulakvelidze, J. Glenn Morris, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Patent number: 6183973Abstract: The present invention is directed to oligonucleotides used as amplification primers and assay probes for specific and sensitive for virulent strains of V. vulnificus. The target sequence of the probes and primers according to present invention is a capsular polysaccharide (CPS) transport gene (wza) of V. vulnificus. These probes can detect wza DNA or RNA in an unknown sample suspected to have pathogenic strains of V. vulnificus including human, animal, or environmental samples. The invention is also directed to in vitro-expressed protein from the cloned wza for production of polyclonal or monoclonal antibody that is specific for the wza gene product and will detect the V. vulnificus Wza protein in a sample comprising unknown protein.Type: GrantFiled: December 4, 1998Date of Patent: February 6, 2001Assignee: UMBI - University of Maryland Biotechnology InstituteInventors: Anita C. Wright, Jan L. Powell, J. Glenn Morris, Jr.
-
Patent number: 6132710Abstract: Gastrointestinal tissue injury and infections are treated by orally administering Lactobacilli strains. The Lactobacilli strains prevent neonatal necrotizing enterocolitis tissue injury and necrotizing enterocolitis in preterm infants. Preterm infants, full-term infants, children and adults as well as animals may be given the Lactobacilli strains. The strains are Lactobacillus salivarius strain ATCC 202196 and Lactobacillus plantarum strain ATCC 202195. Further, the strains may be given individually or as a combination of the two strains. In addition, the strains are useful in treating diarrhea. The Lactobacilli strains normalize and balance bacterial milieu in the gastro-intestinal tract. The Lactobacilli strains may be in lyophilized capsule form. The capsule may be an enteric coated slow-release microcapsule. The Lactobacilli strains may also be administered by means of a naso-gastric tube, especially for preterm infants.Type: GrantFiled: March 17, 1997Date of Patent: October 17, 2000Assignee: ProBiotix, Inc.Inventors: Pinaki Panigrahi, Ira H. Gewolb, J. Glenn Morris, Jr.
-
Patent number: 5653986Abstract: Substantially pure capsular polysaccharide obtained from Vibrio cholerae Bengal serogroup-O139, capsular polysaccharide-protein conjugates thereof, and antibodies having binding specificity to said capsular polysaccharide.Type: GrantFiled: June 6, 1995Date of Patent: August 5, 1997Assignee: University of Maryland at BaltimoreInventors: J. Glenn Morris, Jr., Judith A. Johnson, C. Allen Bush
-
Patent number: 5258284Abstract: Nucleic acid probes specific for pathogenic stains of vibrio vulnificus and methods employing the same, comprising nucleic acid hybridization probes specific for the vvh gene of pathogenic strains of vibrio vulnificus.Type: GrantFiled: January 22, 1991Date of Patent: November 2, 1993Assignee: University of Maryland, School of MedicineInventors: J. Glenn Morris, Jr., Anita Wright